Non-alcoholic fatty liver disease (NAFLD)
NAFLD is currently the most common liver disorder both in the US and Europe. The fatty liver may progress to non-alcoholic steatohepatitis (NASH), which markedly increases the risk of cirrhosis and hepatocellular carcinoma. NAFLD is the hepatic manifestation of the metabolic syndrome and characterizes the majority of patients with type 2 diabetes.
1. To advance our understanding of the prevalence, diagnosis, pathogenesis, prevention and treatment of NAFLD.
2. To enable hepatologists and diabetologists and other specialists in cognate disciplines to interact.
EASD: Official endorsement
Guidelines for the NAFLD Study Group
The NAFLD Study Group will follow the for Guidelines endorsed by the Executive Committee of the EASD (European Association for the Study of Diabetes) on 14 January 2013.